MAMichaela Aichler

Michaela Aichler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michaela Aichler has a total of 118 co-authors. Here are the top co-authors by number of shared publications:

  • Axel Walch

    Research Unit Analytical Pathology, Helmholtz Zentrum München – German Research Center for Environmental Health, Neuherberg, Germany

    5 shared publications
  • Axel Walch

    Research Unit Analytical Pathology, Helmholtz Zentrum München, Neuherberg, Germany

    2 shared publications
  • Jerzy Adamski

    German Research Center for Environmental Health

    2 shared publications
  • Martin Hrabě de Angelis

    Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health Neuherberg, Germany

    2 shared publications
  • Martin Jastroch

    Institute for Diabetes and Cancer, German Center for Diabetes Research (DZD), Neuherberg, Germany

    2 shared publications
  • A. Schäfer

    Research Unit Protein Science, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstraße 1, 85764 Neuherberg, Munich, Germany ; Member of German Center for Diabetes Research (DZD), Ingolstädter Landstraße 1, 85764 Neuherberg, Munich, Germany

    1 shared publication

Latest Publications

  • Levels of Atg5 determine pancreatic tumor formation and metastasis in mice

    by Kalliope Diakopoulos, Kivanc Görgülü, Marija Stevanovic, Angeliki-Faidra Karpathaki, Jiaoyu Ai, Derya Kabacaoglu, Katrin J. Ciecielski, Ezgi Kaya-Aksoy, Dietrich A. Ruess, Sonja M. Wörmann, et al.


  • PAXgene fixation enables comprehensive metabolomic and proteomic analyses of tissue specimens by MALDI MSI

    by Christian Urban, Achim Buck, Jens T. Siveke, Florian Lordick, Birgit Luber, Axel Walch, Michaela Aichler


  • Open Access

    Stabilization and structural analysis of a membrane-associated hIAPP aggregation intermediate

    by Diana C Rodriguez Camargo, Kyle J Korshavn, Alexander Jussupow, Kolio Raltchev, David Goricanec, Markus Fleisch, Riddhiman Sarkar, Kai Xue, Michaela Aichler, Gabriele Mettenleiter, et al.

    Membrane-assisted amyloid formation is implicated in human diseases, and many of the aggregating species accelerate amyloid formation and induce cell death. While structures of membrane-associated intermediates would provide tremendous insights into the pathology and aid in the design of compounds to potentially treat the diseases, it has not been feasible to overcome the challenges posed by the cell membrane. Here, we use NMR experimental constraints to solve the structure of a type-2 diabetes related human islet amyloid polypeptide intermediate stabilized in nanodiscs. ROSETTA and MD simulations resulted in a unique β-strand structure distinct from the conventional amyloid β-hairpin and revealed that the nucleating NFGAIL region remains flexible and accessible within this isolated intermediate, suggesting a mechanism by which membrane-associated aggregation may be propagated. The ability of nanodiscs to trap amyloid intermediates as demonstrated could become one of the most powerful approaches to dissect the complicated misfolding pathways of protein aggregation.


  • N-acyl Taurines and Acylcarnitines Cause an Imbalance in Insulin Synthesis and Secretion Provoking β Cell Dysfunction in Type 2 Diabetes

    by Michaela Aichler, Daniela Borgmann, Jan Krumsiek, Achim Buck, Patrick E. MacDonald, Jocelyn E. Manning Fox, James Lyon, Peter E. Light, Susanne Keipert, Martin Jastroch, et al.


  • Open Access

    Benchmark datasets for 3D MALDI- and DESI-imaging mass spectrometry

    by Janina Oetjen, Kirill Veselkov, Jeramie Watrous, James S McKenzie, Michael Becker, Lena Hauberg-Lotte, Jan Hendrik Kobarg, Nicole Strittmatter, Anna K Mróz, Franziska Hoffmann, et al.

    Background: Three-dimensional (3D) imaging mass spectrometry (MS) is an analytical chemistry technique for the 3D molecular analysis of a tissue specimen, entire organ, or microbial colonies on an agar plate. 3D-imaging MS has unique advantages over existing 3D imaging techniques, offers novel perspectives for understanding the spatial organization of biological processes, and has growing potential to be introduced into routine use in both biology and medicine. Owing to the sheer quantity of data generated, the visualization, analysis, and interpretation of 3D imaging MS data remain a significant challenge. Bioinformatics research in this field is hampered by the lack of publicly available benchmark datasets needed to evaluate and compare algorithms. Findings: High-quality 3D imaging MS datasets from different biological systems at several labs were acquired, supplied with overview images and scripts demonstrating how to read them, and deposited into MetaboLights, an open repository for metabolomics data. 3D imaging MS data were collected from five samples using two types of 3D imaging MS. 3D matrix-assisted laser desorption/ionization imaging (MALDI) MS data were collected from murine pancreas, murine kidney, human oral squamous cell carcinoma, and interacting microbial colonies cultured in Petri dishes. 3D desorption electrospray ionization (DESI) imaging MS data were collected from a human colorectal adenocarcinoma. Conclusions: With the aim to stimulate computational research in the field of computational 3D imaging MS, selected high-quality 3D imaging MS datasets are provided that could be used by algorithm developers as benchmark datasets.


  • Spatially Resolved Quantification of Gadolinium(III)-Based Magnetic Resonance Agents in Tissue by MALDI Imaging Mass Spectrometry after In Vivo MRI

    by Michaela Aichler, Katharina Huber, Franz Schilling, Fabian Lohöfer, Katja Kosanke, Reinhard Meier, Ernst J. Rummeny, Axel Walch, Moritz Wildgruber


  • Open Access

    High fat diet-induced modifications in membrane lipid and mitochondrial-membrane protein signatures precede the development of hepatic insulin resistance in mice

    by M. Kahle, A. Schäfer, A. Seelig, J. Schultheiß, M. Wu, M. Aichler, J. Leonhardt, B. Rathkolb, J. Rozman, H. Sarioglu, et al.


  • Open Access

    Early recognition of lung cancer by integrin targeted imaging in K‐ras mouse model

    by Vladimir Ermolayev, Pouyan Mohajerani, Angelique Ale, Athanasios Sarantopoulos, Michaela Aichler, Gian Kayser, Axel Walch, Vasilis Ntziachristos

    Non-small cell lung cancer is characterized by slow progression and high heterogeneity of tumors. Integrins play an important role in lung cancer development and metastasis and were suggested as a tumor marker; however their role in anticancer therapy remains controversial. In this work, we demonstrate the potential of integrin-targeted imaging to recognize early lesions in transgenic mouse model of lung cancer based on spontaneous introduction of mutated human gene bearing K-ras mutation. We conducted ex vivo and fluorescence molecular tomography-X-ray computed tomography (FMT-XCT) in vivo imaging and analysis for specific targeting of early lung lesions and tumors in rodent preclinical model for lung cancer. The lesions and tumors were characterized by histology, immunofluorescence and immunohistochemistry using a panel of cancer markers. Ex vivo, the integrin-targeted fluorescent signal significantly differed between wild type lung tissue and K-ras pulmonary lesions (PL) at all ages studied. The panel of immunofluorescence experiments demonstrated that PL, which only partially show cancer cell features were detected by αvβ3-integrin targeted imaging. Human patient material analysis confirmed the specificity of target localization in different lung cancer types. Most importantly, small tumors in the lungs of 4-week-old animals could be noninvasively detected in vivo on the fluorescence channel of FMT-XCT. Our findings demonstrated αvβ3-integrin targeted fluorescent imaging to specifically detect premalignant pleural lesions in K-ras mice. Integrin targeted imaging may find application areas in preclinical research and clinical practice, such as early lung cancer diagnostics, intraoperative assistance or therapy monitoring.


  • Open Access

    Lipoic acid inhibits cell proliferation of tumor cells in vitro and in vivo

    by Benedikt Feuerecker, Sabine Pirsig, Christof Seidl, Michaela Aichler, Annette Feuchtinger, Gernot Bruchelt, Reingard Senekowitsch-Schmidtke

    Cancer cells convert glucose preferentially to lactate even in the presence of oxygen (aerobic glycolysis–Warburg effect). New concepts in cancer treatment aim at inhibition of aerobic glycolysis. Pyruvate dehydrogenase converts pyruvate to acetylCoA thus preventing lactate formation. Therefore, the aim of this study was to evaluate compounds that could activate pyruvate dehydrogenase in cancer cells. We investigated the effects of (R)-(+)-α-lipoic acid (LPA) and dichloroacetate (DCA), possible activators of pyruvate dehydrogenase, on suppression of aerobic glycolysis and induction of cell death. The neuroblastoma cell lines Kelly, SK-N-SH, Neuro-2a and the breast cancer cell line SkBr3 were incubated with different concentrations (0.1–30 mM) of LPA and DCA. The effects of both compounds on cell viability/proliferation (WST-1 assay), [18F]-FDG uptake, lactate production and induction of apoptosis (flow cytometric detection of caspase-3) were evaluated. Furthermore, NMRI nu/nu mice that had been inoculated s.c. with SkBr3 cells were treated daily for four weeks with LPA (i.p, 18.5 mg/kg) starting at day 7 p.i.. Tumor development was measured with a sliding calliper and monitored via [18F]-FDG-PET. Residual tumors after therapy were examined histopathologically. These data suggests that LPA can reduce (1) cell viability/proliferation, (2) uptake of [18F]-FDG and (3) lactate production and increase apoptosis in all investigated cell lines. In contrast, DCA was almost ineffective. In the mouse xenograft model with s.c. SkBr3 cells, daily treatment with LPA retarded tumor progression. Therefore, LPA seems to be a promising compound for cancer treatment.